PBA
Paradigm Biocapital Advisors Portfolio holdings
AUM
$2.34B
This Quarter Return
+24.13%
1 Year Return
+13.3%
3 Year Return
+245.82%
5 Year Return
–
10 Year Return
–
AUM
$2.86B
AUM Growth
+$244M
(+9.4%)
Cap. Flow
-$206M
Cap. Flow
% of AUM
-7.22%
Top 10 Holdings %
Top 10 Hldgs %
68.12%
Holding
42
New
7
Increased
15
Reduced
7
Closed
11
Top Buys
| 1 |
Vera Therapeutics
VERA
|
$48.5M |
| 2 |
MoonLake Immunotherapeutics
MLTX
|
$47M |
| 3 |
ONC
BeOne Medicines Ltd. American Depositary Shares
ONC
|
$45M |
| 4 |
Nuvalent
NUVL
|
$43.8M |
| 5 |
Janux Therapeutics
JANX
|
$38M |
Top Sells
| 1 |
Sarepta Therapeutics
SRPT
|
$150M |
| 2 |
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
|
$95.3M |
| 3 |
Ascendis Pharma
ASND
|
$90.6M |
| 4 |
Xenon Pharmaceuticals
XENE
|
$79.7M |
| 5 |
Disc Medicine
IRON
|
$59.3M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Pliant Therapeutics
PLRX
$103M
| $34.8M | 1.18% |
+3,104,486
| New | +$34.8M |
|
27
Keros Therapeutics
KROS
$632M
| $30.5M | 1.03% |
+525,037
| New | +$30.5M |
|
28
Erasca
ERAS
$400M
| $29.1M | 0.99% |
10,668,141
+3,418,141
| +47% | +$9.33M |
|
|
ORKA
29
Oruka Therapeutics, Inc. Common Stock
ORKA
$579M
| $17.6M | 0.6% |
+719,660
| New | +$17.6M |
|
30
Perspective Therapeutics
CATX
$244M
| $12.3M | 0.42% |
919,692
| – | – |
|
|
CMPS
31
Compass Pathways
CMPS
$458M
| $7.31M | 0.25% |
1,160,000
-1,175,926
| -50% | -$7.41M |
|
|
32
Ascendis Pharma
ASND
$12B
| – | – |
-664,307
| Closed | -$90.6M |
|
33
Legend Biotech
LEGN
$6.54B
| – | – |
-1,203,308
| Closed | -$53.3M |
|
|
34
Sarepta Therapeutics
SRPT
$1.95B
| – | – |
-947,574
| Closed | -$150M |
|
35
TScan Therapeutics
TCRX
$106M
| – | – |
-353,886
| Closed | -$2.07M |
|
36
Vor Biopharma
VOR
$253M
| – | – |
-6,457,293
| Closed | -$6.46M |
|
|
VRNA
37
Verona Pharma
VRNA
$9.18B
| – | – |
-721,087
| Closed | -$10.4M |
|
|
38
Xenon Pharmaceuticals
XENE
$2.96B
| – | – |
-2,043,280
| Closed | -$79.7M |
|
|
CERE
39
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| – | – |
-2,330,508
| Closed | -$95.3M |
|
40
BridgeBio Pharma
BBIO
$9.95B
| – | – |
-1,089,492
| Closed | -$27.6M |
|
41
Acrivon Therapeutics
ACRV
$41.8M
| – | – |
-659,724
| Closed | -$3.83M |
|
42
ALX Oncology
ALXO
$54.1M
| – | – |
-1,575,605
| Closed | -$9.5M |
|